Dear valued partners and stakeholders,
I am Eung Joon Jo, CEO of ASTA.
The rapid advancement of AI and computing technologies is driving transformative change across industries worldwide—and the field of healthcare is no exception. Developing more accurate, faster, and cost-effective diagnostic and therapeutic systems is now a global imperative, and ASTA is proud to be at the forefront of this innovation.
Building upon more than a decade of experience in developing and manufacturing medical MALDI-TOF mass spectrometry systems, ASTA is currently developing a Rapid ID-AST platform designed to simultaneously identify pathogens and recommend appropriate antimicrobial treatments—an essential tool for responding swiftly to pandemics and emergency scenarios. This platform is scheduled for launch in 2026. In parallel, we are also developing a high-precision early cancer detection platform, designed for rapid and accurate diagnostics at the earliest stages.
These next-generation platforms integrate cloud-based MALDI-TOF mass spectrometry, reproducibility enhancement software, and AI-driven data analysis—together forming a new diagnostic paradigm. Through this, we aim to compete with the world’s leading technology firms and secure our position in the global market.
Leveraging our accumulated expertise in medical device innovation, ASTA has also expanded into the semiconductor, OLED display, and battery material industries, supplying highly specialized analytical instruments tailored to each field. Our development efforts extend to on-site quality control (QC) systems for industrial production lines. The LDI-TOF system, for example, has proven highly effective in precision analysis of display and battery materials, while the TGA-TOF system enables real-time gas analysis, essential for monitoring etching processes and detecting metallic gases. These technologies are now being expanded for use in semiconductor process gas monitoring systems, among others.
Over the past 20 years, ASTA has remained committed to technological advancement. Today, we are transitioning into a phase of market-responsive commercialization, delivering innovative products that meet real-world demand. We are also accelerating our strategic investments across domestic and international markets, with results expected in the near term.
In healthcare, ASTA is preparing to lead the global market through technology licensing, international distribution partnerships, and the launch of our next-generation Reproducibility Enhanced MALDI-TOF and Rapid Point-of-Care ID-AST platforms.
In industry, we will continue to move ahead of the competition by providing high-speed, high-precision QC equipment and leading the way in delivering cloud-based productivity enhancement platforms.
At ASTA, we are more than a technology provider—we are a diagnostic and analytical solutions partner committed to understanding and solving our customers’ challenges. Every element of our product—from UI/UX to data output formats and result interpretation interfaces—is designed from the user’s perspective, empowering clinicians, researchers, and technicians to focus on what matters most. In industrial settings, our solutions offer the perfect balance of real-time accuracy, stability, and usability, even under demanding conditions.
Looking ahead, ASTA will continue to pursue technological innovation as a means to support healthier lives and sustainable industrial growth. We are committed to becoming a globally trusted and respected leader in diagnostic and analytical technologies.
Thank you for your continued support.
